Hologic acquires Diagenode for $159 million

LabPulse.com staff writers
Feb 28, 2021
2019 02 01 17 54 2200 Hologic Rsna 2018 400

Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand Hologic's molecular diagnostics business internationally.

Diagenode offers clients more than 30 polymerase chain reaction (PCR) tests, as well as a portfolio of devices, kits, reagents, and antibodies for DNA and RNA analysis.

The two firms have had a partnership since 2016 and have collaborated on Panther Fusion assays for group B Streptococcus and Bordetella. Diagenode generated more than $30 million in revenue in the last year, Hologic said.

Latest in Group B Streptococcus
2020 03 18 22 45 6099 2020 03 19 Genital Pathology 20200318221617
Pathologists advance understanding of deadly female genital tract infections
March 18, 2020
2019 08 20 21 21 4020 Luminex Aacc 2019 400
Luminex MRSA test clears FDA
September 30, 2019
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2019 06 26 20 22 6835 Hepatitis Virus 400
NeuMoDx launches 4 new CE-IVD tests
June 25, 2019
Related Stories
2019 08 20 21 43 1377 Hologic Aacc 2019 400
Financial Results
Hologic posts strong Q3 revenues
2019 02 01 17 54 2200 Hologic Rsna 2018 400
Molecular Diagnostics
Ink dries on Hologic's deal to buy Mobidiag
2020 01 02 21 24 9838 Hologic Rsna 2019 400
Financial Results
Hologic's growth continues in Q2
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Group B Streptococcus
Pathologists advance understanding of deadly female genital tract infections
By Emily Hayes
Group A strep is typically found in the mouth, but it can also infect other mucosal areas of the body, with deadly results. The researchers noted that GAS surface proteins cause an estimated 700 million human infections annually around the world, including 15 million in the U.S. GAS is at the root of puerperal sepsis (also known as childbed fever), which is the leading cause of maternal deaths, and it causes necrotizing myometritis (inflammation of the uterine myometrium) as well as severe infections in newborns.
March 18, 2020
2020 03 18 22 45 6099 2020 03 19 Genital Pathology 20200318221617
Luminex MRSA test clears FDA
By LabPulse.com staff writers
The Aries MRSA assay tests directly for MRSA DNA from nasal swabs in patients at risk for nasal colonization. Clearance was granted on September 25 and announced by the company on October 1.
September 30, 2019
2019 08 20 21 21 4020 Luminex Aacc 2019 400
What the rise of urgent care centers means for labs
By Bruce Carlson
The number of urgent care centers in the U.S. is expected to increase from approximately 10,600 currently to more than 12,000 by 2023, according to the report, titled "The Market for Urgent Care Centers" and published August 6. This will produce $3 billion in marginal dollars earned by urgent care centers across the nation in the next five years. For laboratorians and IVD vendors, it is an important area to watch, as urgent care centers increasingly offer point-of-care testing on-premises. Some larger urgent care centers even feature more complex laboratories.
August 15, 2019
2019 06 20 19 12 0495 Hospital Lobby 400
NeuMoDx launches 4 new CE-IVD tests
By LabPulse.com staff writers
The assays work with the company's NeuMoDx 96 and NeuMoDx 288 molecular systems.
June 25, 2019
2019 06 26 20 22 6835 Hepatitis Virus 400
Meridian acquires GenePOC from Debiopharm
By LabPulse.com staff writers
Through the deal, Meridian will gain GenePOC's revogene product for microbial testing, which incorporates polymerase chain reaction (PCR) techniques for rapid testing in cases where infectious diseases are suspected. The product is marketed in the U.S., Europe, and Canada.
April 30, 2019
2019 04 30 22 11 5866 Bacteria 400
Kalorama's notable product launches for clinical labs in Q1 2019
By Bruce Carlson
In the POC segment, one of the breakthrough approvals from the U.S. Food and Drug Administration (FDA) was for the Sangia total prostate-specific antigen (PSA) test by Opko Health (Woburn, MA) in January. The Sangia test is the first POC test that quantitatively measures total PSA in capillary whole blood, and it is approved for use with the digital rectal exam (DRE) to screen for prostate cancer in men 50 years and older. The test can be administered with a finger prick and results are generated in 12 minutes.
April 24, 2019
2019 04 24 21 42 1456 Lab Research 400
Page 1 of 1